Navigation Links
Progen Restructures Manufacturing and Drug Discovery Divisions
Date:3/27/2008

BRISBANE, Australia, March 27 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that it will outsource the commercial manufacture of PI-88. The Progen manufacturing facility at the Brisbane suburb of Darra will be retained as a stand-alone business providing process development services and the manufacture of drug development material. Progen expects the transfer of PI-88 manufacture to occur in the next 12 to 18 months.

Progen will maintain the manufacturing facility with existing contracts as a break even operation, and will be assessing its options to either increase facility profitability through additional manufacturing contracts and/or seek a commercial buyer.

"Our manufacturing division has been of great value and has served Progen very well in the past, having made all PI-88 to date, including the supply to be used in the Phase 3 PATHWAY trial as well as having played and continuing to play an important role in supplying contract manufacturing services globally," said Progen's CEO, Justus Homburg.

"However, as far as PI-88 is concerned, the facility was never designed for the manufacture of commercial quantities, and we intend to contract out commercial PI-88 production to an established large-scale commercial bio-pharmaceutical manufacturer."

Further, following several years of in-house active drug development, the chemistry on newly identified lead compound PG545 has essentially been completed. PG545 has been selected for investigational new drug (IND) enabling studies, which are being outsourced.

The restructure involves 8 redundancies in the manufacturing division and 4 in drug discovery and aims to conserve current cash reserves for driving present and future Progen lead compounds towards commercialization.
In summary, following the decisions taken, Progen will:

-- Contract out the commercial supply of PI-88 to an established

bio-pharmaceutical manufacturing facility that has a long-standing

history of producing commercial bio-pharmaceuticals with FDA approvals;

-- Downsize its manufacturing facility from 17 to 9 FTE staff;

-- Downsize its drug discovery team from 12 to 8 FTE staff; and

-- Retain key staff:

- For continuing development of Progen's discovery heparanase

inhibitor program;

- For biological assessment of the expanded Progen portfolio of

preclinical compounds; and

- To manage the transfer of manufacturing know-how and the submission

of, amongst others, the Chemistry, Manufacturing and Controls (CMC)

parts of the New Drug Application (NDA).

Progen Information:

Linton Burns

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: lintonb@progen-pharma.com

Media and Investor Relations Australia:

Cindy Ingram

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: cindyi@progen-pharma.com

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PI-166 and other drugs, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Progen Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
2. Progeniq Joins Microsoft in Bio IT Alliance
3. Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD)
4. Progentix Orthobiology B.V. Closes Series A Financing Round
5. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
6. Progen Expands Board of Directors
7. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
8. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
9. CME LLC Restructures, Announces Its New Executive Management Team
10. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
11. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... RADNOR, Pa., Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), ... to laboratory and production customers, today reported its financial results ... 2016. Highlights: 4Q16 record ... up 1.0% on an organic basis. ... on an organic basis, while the Americas net sales increased ...
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
Breaking Biology Technology:
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
Breaking Biology News(10 mins):